# The KN510713 Study in Combination With mFOLFIRINOX

Source: https://onco.cc/trials/nct07114861/  
OnCo record `nct07114861` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX in pancreatic ductal adenocarcinoma, run by New Cancer Cure-Bio Co.,Ltd., now recruiting.

## Summary

The KN510713 Study in Combination With mFOLFIRINOX is a phase 1/2 interventional study registered as NCT07114861 by New Cancer Cure-Bio Co.,Ltd., with 30 participants planned, started 2025-12-16 and due to reach its primary completion in 2028-09-22. Interventions recorded: Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX and Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07114861
- Phase: 1/2
- Setting: An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Sponsor: New Cancer Cure-Bio Co.,Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07114861: https://clinicaltrials.gov/study/NCT07114861

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07114861.json